Helicobacter pylori infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: This group will receive the dual therapy regimen consisting of Vonoprazan and Amoxicillin. The Vonoprazan dose is 20 milligrams, twice daily , and the Amoxicillin d
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Age 18-70 years Confirmed Helicobacter pylori infection by stool antigen test and/or rapid urease test and/or gastric biopsy Failure to respond to at least one previous standard first-line H. pylori eradication regimen (treatment-resistant H. pylori) Written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: Known allergy to vonoprazan, lansoprazole, amoxicillin, or other proton pump inhibitors Pregnancy or lactation History of gastric surgery Severe hepatic or renal disease Use of antibiotics or proton pump inhibitors in the last 4 weeks Gastrointestinal malignancy or inflammatory bowel disease Unwillingness to continue cooperation during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome variable of the study is the frequency of Helicobacter pylori eradication. Successful eradication is defined as a negative Stool Antigen Test result during the post-treatment follow-up. Timepoint: The primary outcome variable (Helicobacter pylori eradication) will be measured four weeks after completion of the treatment period. Method of measurement: The primary outcome variable will be measured using the Stool Antigen Test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoumeh Rabbani
Kerman University of Medical Sciences
Outcome results
None listed